Research Highlights

Back to News Archive
Launch of Largest Canadian study on Dementia
The Canadian Consortium on Neurodegeneration in Aging (CCNA) is launching its signature clinical study, the Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND). Over the next two years, the study will enroll 1600 participants, between the ages of 50 and 90 with memory problems from 30 sites across Canada.The goal will be to learn about who is at risk of developing dementia, how early it can be detected and what tests are most effective at detecting it.

"Congratulations to the CCNA on the launch of this pivotal study,” says Jane Philpott, Canada’s Minister of Health. “By guiding new strategies for early detection and intervention, this research will ultimately improve the lives of Canadians living with dementia and their families."

The $8.4 million study is funded by the $31.5 million grant awarded for the creation of the CCNA in 2014 by the Government of Canada through the Canadian Institutes of Health Research and 14 partner organizations from the public and private sectors.

Up to now, most studies of age-related cognitive decline have focused on specific types of dementia in isolation. The goal of COMPASS-ND is to study dementia in all its forms, including cases where there are multiple pathologies involved, such as Alzheimer’s disease and cerebrovascular disease, referred to as “mixed” dementia. This broad approach is being taken in order to investigate what these dementias have in common, as well as what differentiates them. Doing so will help in diagnosing, understanding, and working to prevent the onset of dementia in all its forms. In the case of mixed dementia, study results will help CCNA researchers examine the impacts of different pathologies alone and in combination, and their implications for disease course and treatment.

"The CCNA is already a unique nation-wide collaborative research effort that facilitates Canada's ability to face the challenge of dementia, while setting new inspiring world standards," said Drs. Yves Joanette and Anthony Phillips, co-leads of the CIHR Dementia Research Strategy. “The launch of the COMPASS-ND study will allow this Canadian consortium to untangle the complexity of the brain diseases that cause dementia using an innovative 'real-world' approach. This 'made-in-Canada' perspective makes the COMPASS-ND uniquely positioned to allow major discoveries for the prevention and treatment of the intertwined brain diseases responsible for dementia. COMPASS-ND represents another Canadian première that will be closely followed globally.”

“Our aim is to capture a detailed picture of Canadians living with or at risk for dementia by ‘phenotyping’ individuals, or collecting information across different dementias and focus areas, such as genetics and brain imaging. We believe this approach will help us to better understand the similarities and differences across all forms of dementia, which will lead to improvements in diagnosis and treatment,” says Dr. Howard Chertkow, Scientific Director of the CCNA, Professor at McGill University, neurologist at the Jewish General Hospital, and researcher at the Lady Davis Institute.

Another aim of this study is to further understanding of how dementia impacts women and men differently. It has been shown that women are more likely to develop Alzheimer’s disease than men, while men are more likely to develop vascular dementia than women. What accounts for these discrepancies is little understood and will be a focus of the COMPASS-ND.

Participants will be recruited in large urban centers, such as Montreal, Toronto, and Vancouver, as well as in smaller communities, such as Saint John, NB and Prince George, BC. If you would like to learn more about this study, please contact Mr. Victor Whitehead at (514) 340-8222 ext. 5267 or Brian Kuan at 514 340-8222 ext. 2298

Support research at the Lady Davis Institute - Jewish General Hospital